TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01553201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline, 4cc, one time intramuscular administration
Study: NCT04704271
Drug: Inhaled THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg inhaled THC
Study: NCT04704271
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled placebo (no active cannabinoids)
Study: NCT02291471
Drug: T0001，10mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02291471
Drug: T0001，20mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02291471
Drug: T0001，35mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02291471
Drug: T0001，50mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04177433
Drug: Depo-Medrol Injectable Product
Normalized name: DEPO-Medrol Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid
Study: NCT02356991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02709486
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00737737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00571194
Drug: pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single 10 mg dose of pravastatin will be administered 3 mL blood samples for pravastatin Pharmacokinetic evaluations will be collected at 0.5, 1, 2, 3, 4, 6, and 8 hours. 5 mL blood samples for pravastatin PK and laboratory evaluations will be drawn at pre-dose and 24 hours.~Vital Signs and Physical Exams will also be done throughout the study
Study: NCT03829150
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: clarithromycin (Klaricid) 500 mg bid for 7 days
Study: NCT03221400
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil 2400 mg/m2 IV
Study: NCT01777256
Drug: GSK2586184 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2586184 tablet will be administered orally as twice daily dose of 50 mg (1 x 50 mg tablet) up to 12 weeks.
Study: NCT01777256
Drug: GSK2586184 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2586184 tablet will be administered orally as twice daily dose of (2 X 50 mg tablet) up to 12 weeks.
Study: NCT01777256
Drug: GSK2586184 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2586184 tablet will be administered orally as twice daily dose of 200 mg (1 x 200 mg) up to 12 weeks.
Study: NCT01777256
Drug: GSK2586184 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2586184 tablet will be administered orally as twice daily dose of (2 X 200 mg) up to 12 weeks.
Study: NCT00856713
Drug: NRL972
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of 2 mg NRL972
Study: NCT01777256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablet will be administered orally twice daily up to 12 weeks.
Study: NCT05732181
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patch without drugs
Study: NCT01000610
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-25 mg weekly (oral or parenteral)
Study: NCT00363155
Drug: KRN7000
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02205502
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02932020
Drug: 0.5% marcaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: epidural injection of 2mL 0.5% marcaine
Study: NCT01402180
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01754818
Drug: Bendavia 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01754818
Drug: Bendavia 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01754818
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00500006
Drug: MK0457
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.~Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour.
Study: NCT02216799
Drug: Regular insulin
Normalized name: Regular insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours
Study: NCT01213836
Drug: Placebo matching Seroquel IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.
Study: NCT02507245
Drug: Growth Hormone-Releasing Hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: From Baseline Visit (T0) to 6th Month Visit 0,025 mg/kg Growth Hormone/die. From 6th Month Visit to 12th Month Visit 0,030 mg/Kg Growth Hormone/die.
Study: NCT04049123
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01559935
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
Study: NCT04374799
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two doses of heparin
Study: NCT01431352
Drug: Chinese herbal medicine granules or Chinese herbal medicine granules placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: twice a day for 6 month
Study: NCT01057654
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin 40 mg
Study: NCT00523328
Drug: BG9924
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage administered as per Biogen-idec protocol
Study: NCT01764867
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine may be prescribed for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
Study: NCT04004117
Drug: Fentanyl citrate solution sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution of fentanyl citrate (DIN : 02384124 / 02240434 / 02385406) will be administered sublingually by syringe. The dose is 12,5 mcg.
Study: NCT04004117
Drug: Placebo oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will consist in simple syrup (simple syrup B.P. - NPN: 00050121) administered sublingually with syringe.
Study: NCT04663438
Drug: Chemotherapy Drugs, Cancer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other chemotherapy:Irinotecan;topotecan;Enrotinib;Bevacil
Study: NCT03269799
Drug: Vitamin C 500 MG Oral Capsule
Normalized name: vitamin C 500 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: non surgical periodontal treatment+vitamin C 500 mg/day for 2 months
Study: NCT01139749
Drug: oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsules of 20 mg a day, every other day, for six months
Study: NCT03333499
Drug: YanXinShi placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will take matched 1800 mg YXS placebo pills TID in addition to the optimal combination drug treatment of heart failure
Study: NCT03333499
Drug: YanXinShi pills
Approvals — FDA: no, EMA: no, PMDA: no
Description: participants will take 1800 mg YXS pills TID in addition to the optimal combination drug treatment of heart failure
Study: NCT01602471
Drug: [F-18]RDG-K5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately fifteen (15) patients with carotid artery stenosis \> 69% will undergo an endarterectomy and will be imaged under PET/CT with \[F-18\]RGD-K5
Study: NCT03590379
Drug: CHF5993 pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF/GB pMDI
Study: NCT04727684
Drug: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage adjustment according to the ovarian response.
Study: NCT03590379
Drug: Placebo DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 5993 DPI matched placebo
Study: NCT00956787
Drug: AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.
Study: NCT03840499
Drug: Optimal medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy
Study: NCT01891305
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03382431
Drug: Placebo/vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat doses
Study: NCT03590379
Drug: Placebo pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF 5993 pMDI matched Placebo (direct blinding of active CHF 5993 and CHF 1535 pMDIs)
Study: NCT00854802
Drug: Debio 025 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Debio 025 placebo supplied in soft gel capsules
Study: NCT04104984
Drug: Tocolytic Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: a medication is given to prevent uterine contraction
Study: NCT02065713
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
Study: NCT02065713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The prefilled syringe with placebo will be administrated subcutaneously, once monthly, for 24 weeks.
Study: NCT03715322
Drug: Tobramycin Inhalant Product
Normalized name: tobramycin Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin will be nebulized (300mg twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
Study: NCT03715322
Drug: Natural saline inhalation
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural saline will be nebulized (5ml twice daily) with an ultrasonic nebulizer. A total of two 28-day on-and-off cycles will be scheduled.
Study: NCT03887416
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The comparator will be placebo oral tablet matching dapagliflozin 10 mg. Placebo will be administered through out the planned intervention period of the study (12 weeks).~Dosage form and strength: Green, plain, diamond shaped, film coated tablet (orally). Does not contain active ingredient
Study: NCT04781114
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS002: 300mg(2mL) Q4W; Placebo 2mL Q4W.
Study: NCT02336516
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ® 20mg/kg dose with a maximum dose of 500mg per day for three days
Study: NCT02336516
Drug: Placebo (glucose solution 10%)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03235479
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet to match rimegepant dose QD
Study: NCT01048502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks
Study: NCT03989531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drip infusion over 60 minutes
Study: NCT03662763
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00467831
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin sodium tablet, 20 mg by mouth every night at bedtime.
Study: NCT00467831
Drug: Erythromycin
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin tablet, 333 mg by mouth three times daily.
Study: NCT03553875
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participating children and adolescents with Non-Verbal Learning Disorder and related conditions (NVLD-RC) who meet the eligibility criteria will be randomly assigned to placebo for the course of the 12-week randomized controlled trial (RCT).
Study: NCT01754987
Drug: Ascorbic Acid + Sorafenib
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01076556
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02251977
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of placebo for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
Study: NCT02251977
Drug: mFOLFOX6 or XELOX
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.~XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.~The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient.
Study: NCT04532957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo capsules
Study: NCT01267006
Drug: GSK1325756
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.
Study: NCT01267006
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be available as white film coated GSK1325756 matching tablet which will be administered twice daily by oral route with 240 milliliters of water.
Study: NCT00670033
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive ingredients used as a placebo
Study: NCT00479388
Drug: Comparator: simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: simvastatin (20mg to 40mg) for 12 weeks.
Study: NCT02018094
Drug: Co-amoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.
Study: NCT02018094
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
Study: NCT00382629
Drug: BHT-3009 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00382629
Drug: BHT-3009 1.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00382629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02787317
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin is used in patients undergoing percutaneous coronary intervention.
Study: NCT00594620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01096979
Drug: LIPO-102
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection
Study: NCT01096979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02111850
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5 % in water (D5W) with Mesna 15 mg/kg /day X 2 days over 1 hour.
Study: NCT02485821
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02485821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01901172
Drug: RO5503781
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily for 5 days followed by 23 days rest per cycle
Study: NCT01901172
Drug: RO5503781
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses Days 1 and 11
Study: NCT03658473
Drug: 550 mg naproxen + 300 mg rebamipide + 20 mg rabeprazole.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
Study: NCT03658473
Drug: 550 mg naproxen + placebo + 20 mg rabeprazole
Normalized name: naproxen sodium 550 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 550 mg naproxen 2x daily + placebo of rebamipide 2x daily + 20 mg rabeprazole 1x daily over 7 days.
Study: NCT03658473
Drug: 550 mg naproxen + 300 mg rebamipide + placebo
Normalized name: naproxen sodium 550 MG
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 550 mg naproxen 2x daily + 300 mg rebamipide 2x daily + placebo of rabeprazole 1x daily over 7 days.
Study: NCT04732988
Drug: HSG4112
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral administration
Study: NCT04732988
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral administration
Study: NCT01711749
Drug: Crestor®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation is rosuvastatin calcium tablets, 20mg, currently commercialized by AstraZeneca do Brasil Ltda., under the trademark Crestor®
Study: NCT01711749
Drug: rosuvastatin calcium tablets
Normalized name: Rosuvastatin Calcium
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Test formulation is rosuvastatin calcium tablets, 20 mg, produced by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda.
Study: NCT02194023
Drug: Placebo: PCB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
Study: NCT02194023
Drug: 0.03%NF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
Study: NCT00648024
Drug: Agrylin® Capsules 1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg, single dose fasting
Study: NCT01461941
Drug: E6005
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6005
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
Study: NCT01461941
Drug: E6005 ointment (vehicle)
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
Study: NCT01198834
Drug: Etodolac
Normalized name: Etodolac
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Application of up to two patches at the discretion of the investigator for up to 7 days.
Study: NCT02843659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT01872845
Drug: Pravastatin 40mg
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pravastatin 40mg PO daily for 1year from the day of BES implantation
Study: NCT01872845
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
Study: NCT02960438
Drug: E6011
Normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE6011
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous administration
Study: NCT02960438
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous administration
Study: NCT00517543
Drug: GW856553
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04815395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of placebo orally
Study: NCT01269450
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 200mg vaginal tablets
Study: NCT01522950
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet daily
Study: NCT03121014
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5mg/m\^2 on Day 1, 5 mg/m\^2 on Days 3, 6 and 11
Study: NCT00412737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched to oseltamivir capsule or suspension orally once daily for 12 weeks.
Study: NCT00002829
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infused intravenously over 2 hours daily on Day -7 and -6.
Study: NCT04039919
Drug: Placebo (PSL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be provided matching Padsevonil to maintain the blinding.
Study: NCT01882179
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03728023
Drug: AZD4205
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAD: 5mg, 20mg, 50mg, 100mg and 150mg MAD: low, medium and high dose once daily X14 days
Study: NCT03728023
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose in SAD and once daily for 14 days
Study: NCT00312819
Drug: chemotherapy +/- disulfiram
Approvals — FDA: no, EMA: no, PMDA: no